Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | HPGDS | O60760 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29586157 | 0.87 | HPGDS (0.54) | NPC1SMN1; SMN2RAB9AHPGDSPTPN1 | |
| SCHEMBL2097494 | 0.87 | HPGDS (0.54) | NPC1SMN1; SMN2RAB9AHPGDSPTPN1 | |
| SCHEMBL5278613 | 0.85 | SMN1; SMN2 (0.56) | NPC1SMN1; SMN2RAB9AKMT2AMEN1 | |
| SCHEMBL5051495 | 0.84 | KDM4E (0.49) | NPC1SMN1; SMN2RAB9AHPGDSPTPN1 | |
| SCHEMBL13637552 | 0.81 | FAAH (0.43) | NPC1SMN1; SMN2RAB9AHPGDSPTPN1 | |
| SCHEMBL29799615 | 0.81 | SMN1; SMN2 (0.61) | NPC1SMN1; SMN2RAB9AHPGDSKMT2A | |
| SCHEMBL4355417 | 0.81 | HPGDS (0.55) | NPC1SMN1; SMN2RAB9AHPGDSKMT2A | |
| SCHEMBL21755483 | 0.81 | MEN1 (0.63) | NPC1SMN1; SMN2RAB9AHPGDSPTPN1 | |
| SCHEMBL624930 | 0.81 | SMN1; SMN2 (0.61) | NPC1SMN1; SMN2RAB9AHPGDSKMT2A | |
| SCHEMBL3465985 | 0.81 | HPGDS (0.55) | NPC1SMN1; SMN2RAB9AHPGDSKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| EP-2789607-B1 | PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-20160340349-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| US-20160340349-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| US-20160340349-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9447072-B2 | Pyridone derivative and pharmaceutical containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-9447072-B2 | Pyridone derivative and pharmaceutical containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-9447072-B2 | Pyridone derivative and pharmaceutical containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20160168540-A1 | COMPOSITION FOR MAINTAINING PLATELET FUNCTION | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-1685100-B1 | NOVEL 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS | MERCK SHARP & DOHME (GB) | 2011-02-09 | — | — | EP | disclosed |
| EP-2253630-A1 | Heterocyclic compound and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-20100137281-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2151440-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-02-10 | — | — | EP | disclosed |
| EP-2116530-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-7094777-B2 | 5-HT2A receptor ligands | MERK SHARP & DOHME LTD. | 2006-08-22 | — | — | US | disclosed |
| EP-1685100-A1 | NOVEL 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS | Merck Sharp & Dohme Limited (GB) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005047246-A1 | NOVEL 1, 3-DISUBSTITUTED AZETIDINE DEIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2005-05-26 | — | — | WO | disclosed |
| US-20050101586-A1 | Novel 5-HT2A receptor ligands | MERCK SHARP & DOHME LTD. (GB) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101586-A1 | Novel 5-HT2A receptor ligands | HTR2A, HTR1A, HTR5A | NPC1 1858/4885SMN1; SMN2 644/4885RAB9A 1740/4885 |
| US-20160340349-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | PLPBP, PDXK, PNPO | NPC1 3997/4885SMN1; SMN2 3497/4885RAB9A 2407/4885 |
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | PNPO, PDXK, PLPBP | NPC1 3432/4885SMN1; SMN2 3411/4885RAB9A 2835/4885 |
| US-20160168540-A1 | COMPOSITION FOR MAINTAINING PLATELET FUNCTION | PF4, F2, PFKP | NPC1 4503/4885SMN1; SMN2 2786/4885RAB9A 1837/4885 |
| US-20100137281-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | PCSK9, APOB, REN | NPC1 118/4885SMN1; SMN2 2261/4885RAB9A 3399/4885 |
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | UACA, IL6, IL6ST | NPC1 3128/4885SMN1; SMN2 4704/4885RAB9A 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.